A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum

Daniel L. Gillen, Frank L. Meyskens, Timothy R. Morgan, Jason A. Zell, Robert Carroll, Richard Benya, Wen Pin Chen, Allen Mo, Chris Tucker, Asmita Bhattacharya, Zhiliang Huang, Myra Arcilla, Vanessa Wong, Jinah Chung, Rachel Gonzalez, Luz Maria Rodriguez, Eva Szabo, Daniel W. Rosenberg, Steven M. Lipkin

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum'. Together they form a unique fingerprint.

Medicine & Life Sciences